Patient entered the study at the Mobile Heart Specialists P.In Mobile, Ala.Study will evaluate the antiplatelet medicine CGT-2168, which is abination of clopidogrel (currently marketed by Bristol-Myers Squibb Co.Sanofi-Aventis as Plavix(R)) and a gastroprotectant (omeprazole) in a single pill.By Cogentus, CGT-2168 is designed to provide protective cardiovascular benefits while reducing potentially serious gastrointestinal side effectsmonly associated with dual antiplatelet therapy.Is an important milestone for Cogentus that holds promise for the millions of patients who are prescribed dual antiplatelet treatment," said Cogentus Chairman and Chief Executive Officer Mark A., Ph."We believe CGT-2168 has the potential to reduce significantly the gastrointestinal side effects that can cause patients to interrupt their treatment and furtherpromise their health status.Is an integral part of treating patients with acute coronary syndrome and has been shown to be effective in preventing major cardiovascular events.Thebination of clopidogrel and aspirin is associated with gastrointestinal bleeding, which in some cases requires hospitalization and can even result in death.Global trial is known as COGENT-1 (Clopidogrel and the Optimization of Gastrointestinal Events Trials) and is part of a clinical program expected to enroll more than 4,000 patients at hundreds of sites in the United States, Canada, Europe and South America.Patients who participate in the study, approximately half will receive clopidogrel and aspirin; the other half will receive CGT-2168 (clopidogrel plus omeprazole) and aspirin.Will be assessed regularly for any gastrointestinal side effects such as bleeding and ulcers as well as receive ongoing monitoring of their cardiovascular status.Patients interested in obtaining more information about COGENT-1 should go to .COGENTUS Cogentus Pharmaceuticals, Inc.Menlo Park, CA, is a privately held specialty pharmaceuticalpany founded in 2006.() ismitted to bing a premier developer of innovative, fixed-dosebination prescription medicines serving unmet medical needs that drive significantmercial opportunities.Is a registered trademark of Sanofi-Aventis.Pharmaceuticals Inc.WAS THIS ARTICLE?Not Very.Read more Statin linked to sleep disruption
Get more On what criteria is the choice of antihypertensive made for a patient with or with a predisposition to diabetes? would atenolol and bendroflumethiazide be appropriate?
